<DOC>
	<DOCNO>NCT00823940</DOCNO>
	<brief_summary>The study investigate whether GSK1362885 safe well-tolerated administer normal healthy subject . The study also measure blood level study drug determine body process drug ( pharmacokinetics ) effect drug body ( pharmacodynamics ) .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Safety Tolerability GSK1362885 Healthy Normal Subjects</brief_title>
	<detailed_description>GSK1362885 glycogen phosphorylase inhibitor target treatment Type 2 Diabetes Mellitus reduce hepatic glucose output . This study investigate safety , tolerability , pharmacokinetics , pharmacodynamics single dos GSK1362885 administer healthy volunteer . A glucagon challenge test use stimulate hepatic glucose output order evaluate liver glycogen phosphorylase inhibition GSK1362885 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female 18 55 year age , inclusive , time signing informed consent . A female subject eligible participate nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea BMI within range 20.0 31.9 kg/m2 ( inclusive ) . Capable give write informed consent , include compliance requirement restriction list consent form . Normal cardiac function ECG parameter , per protocol . No significant rhythm abnormality Screening Holter ECG record . A subject eligible inclusion study follow criterion apply : The subject positive prestudy drug/alcohol screen . A minimum list tobacco/drugs screen include amphetamine , barbiturate , cocaine , opiates , cannabinoids benzodiazepine . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . History regular alcohol consumption within 6 month study define average weekly intake &gt; 14 drinks/week men &gt; 7 drinks/week woman . History sensitivity heparin heparininduced thrombocytopenia . History glycogen storage disease Unable unwilling abstain : Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication final postdose assessment treatment level . Caffeineor xanthinecontaining product 24 hour prior dose final postdose assessment treatment level . Use illicit drug Alcohol 24 hour prior dose final postdose assessment treatment level . Strenuous exercise 48 hour prior blood collection clinical laboratory test . Subjects may participate light recreational activity study ( e.g. , watch television , read ) . History uncorrected thyroid dysfunction abnormal thyroid function test assess TSH free T4 screening Pregnant female determine positive serum urine hCG test screen prior dosing . Lactating female . History gastrointestinal hepatic condition could impact absorption investigational compound . Significant ECG abnormality define per protocol Resting systolic blood pressure &lt; 80 mmHg &gt; 150 diastolic blood pressure &lt; 60 mmHg &gt; 90 mmHg screening . Resting heart rate outside range 45 100 bpm . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody . A positive test HIV antibody . A fasting triglyceride level &gt; 400mg/dL ( 4.45mmol/L ) . Anemia define hemoglobin concentration &lt; 11.0g/dL male &lt; 10.0g/lL female . Significant renal disease manifest one following : Creatinine clearance &lt; 80 mL/min . ( estimate serum creatinine ( SCr ) demographic data use MDRD calculation ) : Urine protein/creatinine ( mg/mg ) ratio &gt; 2.5 ; urine albumin concentration &gt; 300 g/mg creatinine . Known loss kidney either surgical ablation , injury , disease Subjects value outside specify range follow key clinical laboratory test Screening readmission treatment period . Laboratory test may repeat confirm eligibility prior dosing : Liver function test : ALT , Direct Bilirubin , Albumin 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) Electrolytes : Sodium +/ 5mEq/L outside normal reference range , potassium Calcium 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1.x ULN ) . Metabolic : Glucose 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 x ULN ) , Total Cholesterol &gt; 240mg/dl . Muscle : CPK &gt; 2 x ULN . Hematology : Hemoglobin , WBC Neutrophils , Platelets 10 % outside normal reference range ( &lt; 0.9 x LLN &gt; 1.1 . x ULN ) . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) prohibit 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication final postdose assessment , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Unable unwilling discontinue aspirin use study . Subjects take lowdose aspirin cardiovascular prophylaxis ( 81 mg less ) eligible participate study , aspirin must discontinue Screening Followup visit . Other Where participation study would result donation blood blood product excess 500 mL within 56 day period . Unwillingness inability follow procedure outline protocol . As result medical interview , physical examination , screen investigation , investigator considers subject unfit study . Subject either immediate family member participate investigator , study coordinator , employee investigator ; member staff conduct study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>FTIH</keyword>
	<keyword>Glucagon</keyword>
	<keyword>Safety</keyword>
	<keyword>GSK1362885</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacodynamics</keyword>
</DOC>